Cargando…

Profile of extended-release oxycodone/acetaminophen for acute pain

This article provides a historical and pharmacological overview of a new opioid analgesic that boasts an extended-release (ER) formulation designed to provide both immediate and prolonged analgesia for up to 12 hours in patients who are experiencing acute pain. This novel medication, ER oxycodone/ac...

Descripción completa

Detalles Bibliográficos
Autor principal:	Bekhit, Mary Hanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621217/ https://www.ncbi.nlm.nih.gov/pubmed/26527898 http://dx.doi.org/10.2147/JPR.S73567

Ejemplares similares

The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2015)

Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets
por: Franke, Ryan M, et al.
Publicado: (2015)

Developments in managing severe chronic pain: role of oxycodone–naloxone extended release
por: Fanelli, Guido, et al.
Publicado: (2015)

Oxycodone Controlled Release in Cancer Pain Management
por: Biancofiore, Giuseppe
Publicado: (2006)

Epidural Oxycodone for Acute Pain
por: Piirainen, Panu, et al.
Publicado: (2022)

Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain
por: De Santis, Stefano, et al.
Publicado: (2021)

Oxycodone DETERx(®): A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain
por: Gudin, Jeff
Publicado: (2016)

Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone
por: Haeseler, Gertrud, et al.
Publicado: (2017)

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain
por: Pergolizzi, Joseph, et al.
Publicado: (2018)

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
por: Pergolizzi, Joseph V, et al.
Publicado: (2018)

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics
por: Coplan, Paul M, et al.
Publicado: (2013)

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
por: Setnik, Beatrice, et al.
Publicado: (2017)

Severe Acetaminophen Toxicity From the Use of Oxycodone-Acetaminophen With Normal Liver Function Tests and a Completely Asymptomatic Course of Hospitalization
por: Haider, Muhammad Adnan, et al.
Publicado: (2023)

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective
por: Ferrarese, Fabio, et al.
Publicado: (2008)

Pain therapy with oxycodone/naloxone prolonged-release combination: case report
por: Błaszczyk, Feliks, et al.
Publicado: (2013)

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial
por: Lee, Kyung-Hee, et al.
Publicado: (2017)

The place of oxycodone/naloxone in chronic pain management
por: Leppert, Wojciech
Publicado: (2013)

Acute Abdomen in a Patient with Cancer Pain on Oxycodone
por: Kishine, Naomi, et al.
Publicado: (2011)

Use of Oxycodone in Pain Management
por: Moradi, Mohammad, et al.
Publicado: (2012)

A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin
por: Olatoke, Oluwadara, et al.
Publicado: (2022)

Evaluation of the effect of managing oxycodone/acetaminophen as a psychotropic medicine: An interrupted time-series study
por: Xiang, Cheng, et al.
Publicado: (2023)

Impact of Oxycodone HCl Extended-release Formulary Restrictions on Extended-release Opioid Market Share, Healthcare Resource Utilization and Costs in Commercial and Medicare Plans
por: Wade, Rolin L., et al.
Publicado: (2017)

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
por: Sessler, Nelson E, et al.
Publicado: (2014)

Intractable restless legs syndrome: role of prolonged-release oxycodone–naloxone
por: de Biase, Stefano, et al.
Publicado: (2016)

Role of Oxycodone Hydrochloride in Treating Radiotherapy-Related Pain
por: Wang, Yinxia, et al.
Publicado: (2020)

Oxycodone hydrochloride immediate-release analgesic for managing severe pain: abuse-deterrent formulations
por: Kibbe, AH, et al.
Publicado: (2018)

Controlled Release of Oxycodone as an Opioid Titration for Cancer Pain Relief: A Retrospective Study
por: Zhao, Shen, et al.
Publicado: (2020)

In response to Gudin et al. — Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties
por: Crudele, Nancy T., et al.
Publicado: (2017)

A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients
por: Nosek, Krzysztof, et al.
Publicado: (2017)

Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350
por: Poulsen, Jakob L, et al.
Publicado: (2018)

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
por: Webster, Lynn R., et al.
Publicado: (2019)

Extended-release morphine sulfate in treatment of severe acute and chronic pain
por: Balch, Robert J, et al.
Publicado: (2010)

Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone
por: Nataatmadja, Melissa, et al.
Publicado: (2016)

A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief)
por: Inoue, Satoshi, et al.
Publicado: (2017)

Simultaneous determination of acetaminophen and oxycodone in human plasma by LC–MS/MS and its application to a pharmacokinetic study
por: Lu, Wei, et al.
Publicado: (2018)

Economic Study on the Impact of Side Effects in Patients Taking Oxycodone Controlled-Release for Noncancer Pain
por: Anastassopoulos, Kathryn P., et al.
Publicado: (2012)

Single- and multiple-dose pharmacokinetics of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) compared with immediate-release hydrocodone bitartrate/ibuprofen and immediate-release tramadol HCl/acetaminophen
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Effects of pharmacogenetic profiles on pediatric pain relief and adverse events with ibuprofen and oxycodone
por: Ali, Samina, et al.
Publicado: (2023)

Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients
por: Lauretti, G R, et al.
Publicado: (2003)

Healthcare Costs And Resource Utilization In Chronic Pain Patients Treated With Extended-Release Formulations Of Tapentadol, Oxycodone, Or Morphine Stratified By Type Of Pain: A Retrospective Claims Analysis, 2012–2016
por: Zah, Vladimir, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5cp20c4rkbjvd6u8bep5i4554c